Endo Health Solutins, Inc. | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Endo Health Solutins, Inc.

Sort by

Viewing results 1‒25 of 33

Special ReportJapan and Sustainability
Care homes in Japan use big data to boost caregivers and lighten workloads
...Nearly 690,000 additional nurses will be required by 2040 to meet demand, says the health ministry....
July 2, 2023
US opioid epidemic
US states near $26bn opioid settlement with J&J, drug distributors
...Its case against Endo, Teva, and Allergan is currently being tried in state court. The settlement payments to New York will begin this summer and continue over the next 17 years....
July 20, 2021
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
US opioid epidemic
J&J to pay $230m to settle New York state opioid case
...It also targeted distributors including McKesson, Cardinal Health and Amerisource Bergen....
June 26, 2021
US opioid epidemic
J&J verdict hits share prices across opioid industry
...This month, Endo announced it had settled in principle by agreeing to pay $10m and up to $1m in products to two plaintiff counties in Ohio....
August 27, 2019
FT Magazine
Opioids, bribery and Wall Street: the inside story of a disgraced drugmaker
...The US is now consumed by another public health disaster. Yet the coronavirus pandemic could end up exacerbating the opioid epidemic....
June 19, 2020
US opioid epidemic
US opioid trial to go ahead after settlement talks fail
...Drug distributor stocks also dropped: Cardinal Health lost 3 per cent to $50.02, McKesson fell 3.1 per cent to $147.56, and AmerisourceBergen was down 1 per cent to $89.64....
October 18, 2019
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
News in-depthThe Big Read
US seeks a fix for its opioid addiction
...AmerisourceBergen and Cardinal Health; and drugstore chains such as Walgreens and CVS....
September 11, 2017
News in-depthWeek in Review
Week in review, December 16
...The moves come as policymakers struggle to get to grips with a drug addiction epidemic that claimed more than 59,000 lives last year, and which has been declared a public health emergency by Donald Trump...
December 15, 2017
US & Canadian companies
FTC sues Endo over ‘pay for delay’ deals
...Some investors argue that Endo is similarly overly-reliant on debt-fuelled deal making and high drug prices....
March 31, 2016
Inside BusinessJonathan Ford
Valeant is the latest troubled roll-up to unravel
...Valeant, for instance, ended up going toe to toe with another roll-up, Endo, in the bidding war for Salix. But most platform companies ultimately unwind because they depend excessively on momentum....
March 20, 2016
High yield bonds
Music shifts for credit investors in 2015
...Fears surrounding Valeant reverberated through to other junk-rated healthcare companies, including Endo International and Mallinckrodt....
December 30, 2015
High yield bonds
Healthcare junk bonds sting investors
...The three companies — Valeant, Endo and Mallinckrodt — have levered up over the past two years in aggressive expansions....
October 1, 2015
The FT ViewPharmaceuticals sector
Shkreli and the true cost of high drug prices
...But there is also a pressing need for the government to give public health systems greater freedom to negotiate prices....
December 22, 2015
LexUS & Canadian companies
Endo/Par: too much of a good thing
...Why, then, is the market so tepid on Endo’s $8bn cash and stock purchase of Par, a generics company? After Monday’s announcement, Endo’s shares fell 5 per cent....
May 18, 2015
US & Canadian companies
Endo to buy Par from TPG Capital in $8bn cash-and-shares deal
...The acquisition will make Endo a top-five global generic drugmaker by US sales, the company said on Monday....
May 18, 2015
FT Live
Global Private Banking Awards 2024
Celebrating excellence in wealth management
Thursday, 7 NovemberThe Landmark London, London, UK
US & Canadian companies
Endo looks to crash $14.5bn Valeant-Salix deal
...If Endo were unable to close the deal until the second quarter of this year, the approval date and Endo shareholder vote could be “uncomfortably close”, resulting in a higher chance of the deal falling apart...
March 11, 2015
Currencies
Valeant issues bonds to fund Salix bid
...Endo’s unexpected offer for the US gastrointestinal drugmaker jarred market participants when it was first announced on Wednesday, said a trader....
March 12, 2015
US & Canadian companies
Raised offer from Valeant knocks Endo out of Salix race
...The offer narrowly exceeded a cash-and-shares bid from Endo, worth about $172.50 at Friday’s prices, prompting the smaller company to pull out of the race....
March 16, 2015
US & Canadian companies
Actavis rewrites ‘big pharma’ playbook
...Mallinckrodt and Endo, both based in low-tax Dublin, are smaller, but have proven themselves to be serial acquirers....
March 26, 2015
Currencies
Healthcare sector leads feverish M&A activity
...Analysts say the ‘eat or be eaten’ mindset will drive further deal activity in the coming months, as smaller drug companies such as Endo Pharmaceuticals and Mallinckrodt look to challenge their larger rivals...
March 30, 2015
US & Canadian companies
Valeant agrees to buy Salix for $14.5bn
...The Canadian group fended off interest from other parties including UK-based Shire and Dublin-headquartered Endo....
February 22, 2015
Global Economy
Resigned Japanese voters set to back Abe
...A health club in Nagoya is waiving the Y2,750 charge for a three-hour sauna....
December 12, 2014
News in-depthThe Big Read
Tax avoidance: The Irish inversion
...Endo’s Mr Davis remains untroubled....
April 29, 2014
US & Canadian companies
Pfizer sets stage for corporate showdown
...Companies including Horizon Pharma, Perrigo, Actavis, Alkermes, Jazz Pharmaceuticals, Covidien, Forest Laboratories and Endo Health Solutions have moved to Ireland, in deals expected to cut companies’ overall...
April 28, 2014
US & Canadian companies
Medicine Patent expiries trigger pain drugs battle
...But, in the case of prescription painkillers generally, the FDA must eventually decide whether it can discriminate against generic drug companies on the grounds of the growing public health problem....
December 4, 2012

Previous pagePage 1 of 2Next page